Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Issued (2021 - 2025)

Rani Therapeutics Holdings has reported Shares Issued over the past 5 years, most recently at -$3.5 million for Q3 2025.

  • Quarterly results put Shares Issued at -$3.5 million for Q3 2025, down 139.73% from a year ago — trailing twelve months through Dec 2025 was $408000.0 (down 95.23% YoY), and the annual figure for FY2025 was $408000.0, up 700.0%.
  • Shares Issued for Q3 2025 was -$3.5 million at Rani Therapeutics Holdings, down from $3.9 million in the prior quarter.
  • Over the last five years, Shares Issued for RANI hit a ceiling of $73.6 million in Q4 2021 and a floor of -$3.5 million in Q3 2025.
  • Median Shares Issued over the past 5 years was $40000.0 (2023), compared with a mean of $5.5 million.
  • Biggest five-year swings in Shares Issued: tumbled 992.5% in 2024 and later soared 4243.62% in 2025.
  • Rani Therapeutics Holdings' Shares Issued stood at $73.6 million in 2021, then plummeted by 100.2% to -$148000.0 in 2022, then surged by 127.03% to $40000.0 in 2023, then tumbled by 992.5% to -$357000.0 in 2024, then crashed by 888.52% to -$3.5 million in 2025.
  • The last three reported values for Shares Issued were -$3.5 million (Q3 2025), $3.9 million (Q2 2025), and $42000.0 (Q1 2025) per Business Quant data.